CClinicalTrials.gg
CompletedNCT03469986Updated Nov 8, 2023

A Multi-site Comparison of Social Visual Engagement to Clinical Diagnosis for Autism Spectrum Disorder

An observational study in Autism Spectrum Disorder, sponsored by EarliTec Diagnostics, Inc. Completed at 6 sites in United States. Open to participants aged 16 Months to 30 Months. Per ClinicalTrials.gov, last updated 2023-11-08.

Sponsored by EarliTec Diagnostics, Inc · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
505
Ages
16 Months to 30 Months
Sex
All
01

Study summary

This is an outpatient, multicenter, prospective, pivotal, double-blind, within-subject comparison trial of the Marcus Autism Center Investigational Device (MAC-ID) diagnostic procedure relative to the gold-standard (reference standard), current best practice expert clinician diagnosis (ECD) of Autism Spectrum Disorder (ASD) in children 16-30 months of age.

Consecutive pediatric patients from the intended population (i.e. children 16-30 months of age) recruited from pediatric referrals and general advertisements will be the subjects of this trial. All subjects will undergo the MAC-ID diagnostic procedure (test). All subjects will also undergo the current best practice clinical diagnostic procedure, using standardized ASD diagnostic instruments and standardized developmental assessments, to produce the ECD of each child's ASD status (reference/gold standard).

The study consists of a screening phase and diagnostic evaluation phase to assess the validity (sensitivity and specificity), safety, and effectiveness of the MAC-ID when used to diagnose ASD.

Subjects will be enrolled in the trial for a period of 1 day. The trial will be completed in approximately 12 months.

The overall study objective is to assess the safety and effectiveness of the MAC-ID to accurately diagnose ASD (primary analysis), as well as to accurately assess severity of ASD (secondary analysis) in very young pediatric subjects.

The primary endpoints of this study are the diagnostic result from the MAC-ID and the diagnostic results from the ECD evaluation, both of which are either positive or negative for ASD. Each subject will undergo the Social Developmental Testing Device procedure and an examination by a clinical expert in the field of ASD diagnosis; all study center site personnel (including the expert clinicians responsible for the ECD evaluation) will be blinded to MAC-ID results.

02

Conditions studied

03

Who can participate

Ages eligible
16 Months to 30 Months
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Subjects will be recruited on the basis of concern for ASD, including children who a parent, caregiver, or clinician suspects may have ASD as well as children who are not suspected to have an ASD.

Inclusion criteria

Subjects must meet all of the following inclusion criteria to participate in this study:

  1. Boys and girls between 16 and 30 months of age
  2. Generally healthy with no acute illnesses by physical examination
  3. Normal or corrected-to-normal vision, in terms of visual acuity and oculomotor function, sufficient to watch short videos. Adequate hearing to hear material presented in videos
  4. Subject and parent can communicate meaningfully in English with the principal investigator and the clinical study site staff
  5. Subject's parent or guardian is able to read and understand the informed consent form
  6. Parent voluntarily provides written informed consent

Exclusion criteria

Exclusion Criteria:

Any subject who meets any of the exclusion criteria will be excluded from participation in this study:

  1. Known genetic disorders (e.g., Fragile X, Williams Syndrome, Tuberous Sclerosis, Muscular Dystrophy, Neurofibromatosis, Down Syndrome)
  2. Severe hearing or visual impairment as determined on physical examination (e.g., congenital nystagmus, congenital cataracts, previous diagnosis of severe hearing deficits by otoacoustic emissions or auditory brainstem response)
  3. Acute illnesses likely to prevent successful or valid data collection, i.e., conjunctivitis, fever, uncontrolled allergy symptoms, etc.
  4. Uncontrolled epilepsy or seizure disorder
  5. History or presence of a clinically significant medical disease, or a mental state that might confound the study or be detrimental to the subject as determined by the investigator
  6. Acute exacerbations of chronic illnesses likely to prevent successful or valid data collection
  7. Receiving therapies that may affect vision, i.e., currently receiving or have received the following therapies within 2 weeks of screening: topiramate, chlorpromazine, thioridazine, prednisone, prednisolone (including ophthalmic solutions and ointments), diphenhydramine, or hydroxyzine; or have received ophthalmic antibiotics within 3 days of screening: tobramycin, ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin and ofloxacin solutions and/or bacitracin ointment
  8. Receiving therapies that may affect the ability to focus attention on the videos, i.e., if on central nervous system (CNS) stimulants, CNS depressants, or anticonvulsants, dose must be stable (same dose for at least 2 weeks).
  9. Known allergies or sensitivity to the plastic, leather, or metal components used in the materials of the Social Developmental Testing Device seat
  10. Unable or unwilling to sit in a car seat, e.g., child has tantrums on nearly all occasions when placed in a car seat and tantrums do not subside within 5 minutes
04

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
505 participants (actual)
Patient registry
No

Groups and cohorts

  • Autism Spectrum Disorder

    Children who meet criteria based on expert clinical diagnosis for autism spectrum disorder will be tested with the Marcus Autism Center Investigational Device and expert clinical assessment.

    Device: Marcus Autism Center Investigational Device

  • Non-autism Spectrum Disorder

    Children who do not meet criteria for autism spectrum disorder based on expert clinical diagnosis will be tested with the Marcus Autism Center Investigational Device and expert clinical assessment.

    Device: Marcus Autism Center Investigational Device

Interventions

  • DeviceMarcus Autism Center Investigational Device

    This trial will ascertain whether the binary results of autism or not-autism as determined by the Marcus Autism Center Investigational Device match expert clinical diagnostic opinion. The investigational device is designed to measure visual attention to social information in the environment relative to normative, age-specific benchmarks; these measurements assess presence (primary efficacy outcome) and severity (secondary outcomes) of autism spectrum disorder in 16- to 30-month-old children.

05

What researchers measure

Primary outcomes

  1. Presence of Autism Spectrum Disorder

    In a sample of 400, 200 ASD and 200 non-ASD, the investigational device binary determination of ASD versus non-ASD will match the clinician best estimate diagnosis with 70/70 sensitivity and specificity

    Time frame: 1 day

Secondary outcomes

  1. Social disability index

    Using the Autism Diagnostic Observation Schedule, 2nd Edition, does the degree of deviation of visual engagement indicate the severity of autism symptomatology

    Time frame: 1 day

  2. Verbal Ability Index

    Using the verbal domains of the Mullen Scales of Early Learning, does the degree of does the degree of deviation of visual engagement indicate the level of verbal abilities

    Time frame: 1 day

  3. Nonverbal Ability Index

    Using the nonverbal domain of the Mullen Scales of Early Learning, does the degree of does the degree of deviation of visual engagement indicate the level of nonverbal abilities

    Time frame: 1 day

06

Study locations

6 sites
  • Southwest Autism Research and Resource Center
    Phoenix, Arizona 85006, United States
  • University of California San Francisco
    San Francisco, California 94143, United States
  • Emory University
    Atlanta, Georgia 30329, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Cincinnati Children's Hospital
    Cincinnati, Ohio 45229, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
07

References and documents

Publications

  • Jones W, Klaiman C, Richardson S, Lambha M, Reid M, Hamner T, Beacham C, Lewis P, Paredes J, Edwards L, Marrus N, Constantino JN, Shultz S, Klin A. Development and Replication of Objective Measurements of Social Visual Engagement to Aid in Early Diagnosis and Assessment of Autism. JAMA Netw Open. 2023 Sep 5;6(9):e2330145. doi: 10.1001/jamanetworkopen.2023.30145. PubMed 37669054 ↗
  • Jones W, Klaiman C, Richardson S, Aoki C, Smith C, Minjarez M, Bernier R, Pedapati E, Bishop S, Ence W, Wainer A, Moriuchi J, Tay SW, Klin A. Eye-Tracking-Based Measurement of Social Visual Engagement Compared With Expert Clinical Diagnosis of Autism. JAMA. 2023 Sep 5;330(9):854-865. doi: 10.1001/jama.2023.13295. PubMed 37668621 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03469986
Lead sponsor
EarliTec Diagnostics, Inc
Responsible party
Sponsor
First posted
Mar 19, 2018
Start date
Apr 7, 2018
Primary completion
May 31, 2019
Completion
May 31, 2019
Last update
Nov 8, 2023

Study contacts

Cheryl Klaiman, PhD
principal investigator · Children's Healthcare of Atlanta and Emory University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion